Ironwood Pharmaceuticals, Inc.
Symbool: IRWD
NASDAQ
6.74
USDMarktprijs vandaag
-1.0492
Koers/Winst Verhouding
0.1032
Koers/Winst Groei Verhouding
1.07B
MRK Kapitalisatie
- 0.00%
DIV Rendement
Ironwood Pharmaceuticals, Inc. (IRWD) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 499.18 | 92.2 | 656.2 | 620.1 | |||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.net-receivables | 444.67 | 129.1 | 115.5 | 114 | |||||||||||||||||
balance-sheet.row.inventory | 1.58 | 0 | 1.3 | 1.3 | |||||||||||||||||
balance-sheet.row.other-current-assets | 67.24 | 12 | 7.7 | 9.8 | |||||||||||||||||
balance-sheet.row.total-current-assets | 1012.67 | 233.3 | 780.6 | 745.2 | |||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 73.45 | 18.2 | 20.3 | 22.9 | |||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.intangible-assets | 15.14 | 3.7 | 0 | 0 | |||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 15.14 | 3.7 | -15.1 | -24.5 | |||||||||||||||||
balance-sheet.row.long-term-investments | 1.02 | 0 | 15.1 | 24.5 | |||||||||||||||||
balance-sheet.row.tax-assets | 920.14 | 212.3 | 283.7 | 333.3 | |||||||||||||||||
balance-sheet.row.other-non-current-assets | 14.75 | 3.6 | 15.9 | 25.5 | |||||||||||||||||
balance-sheet.row.total-non-current-assets | 1024.5 | 237.8 | 319.9 | 381.7 | |||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-assets | 2037.17 | 471.1 | 1100.5 | 1126.9 | |||||||||||||||||
balance-sheet.row.account-payables | 22.25 | 7.8 | 0.5 | 0.9 | |||||||||||||||||
balance-sheet.row.short-term-debt | 610.44 | 202.7 | 3.1 | 120 | |||||||||||||||||
balance-sheet.row.tax-payables | 9.16 | 1.2 | 0.7 | 0.2 | |||||||||||||||||
balance-sheet.row.long-term-debt-total | 2062.38 | 498.3 | 412.9 | 355.8 | |||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||||
balance-sheet.row.other-current-liab | 421.43 | 64.3 | 22 | 1.3 | |||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 2167.32 | 541.3 | 422.6 | 359.3 | |||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.capital-lease-obligations | 68.57 | 14.5 | 19.7 | 21.6 | |||||||||||||||||
balance-sheet.row.total-liab | 3281.83 | 817.4 | 448.1 | 521 | |||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.common-stock | 0.63 | 0.2 | 0.2 | 0.2 | |||||||||||||||||
balance-sheet.row.retained-earnings | -6811.77 | -1698.6 | -696.4 | -937.6 | |||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -4.71 | -3 | 0 | 0 | |||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 5571.19 | 1355.2 | 1348.6 | 1543.4 | |||||||||||||||||
balance-sheet.row.total-stockholders-equity | -1244.65 | -346.3 | 652.4 | 605.9 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 2037.17 | 471.1 | 1100.5 | 1126.9 | |||||||||||||||||
balance-sheet.row.minority-interest | -3.54 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-equity | -1248.19 | -346.3 | 652.4 | 605.9 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 2037.17 | - | - | - | |||||||||||||||||
Total Investments | 1.02 | 0 | 15.1 | 24.5 | |||||||||||||||||
balance-sheet.row.total-debt | 2687.36 | 715.5 | 415.9 | 475.8 | |||||||||||||||||
balance-sheet.row.net-debt | 2188.18 | 623.4 | -240.3 | -144.3 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -1080.78 | -1002.2 | 175.1 | 528.4 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 1.8 | 1.6 | 1.4 | 1.5 | |||||||||||||||||
cash-flows.row.deferred-income-tax | 61.63 | 72.6 | 65.7 | -333.3 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 33.26 | 32 | 27 | 22.3 | |||||||||||||||||
cash-flows.row.change-in-working-capital | 1.67 | 11.3 | 2.8 | 17.7 | |||||||||||||||||
cash-flows.row.account-receivables | 43.73 | 0.9 | 8 | 7.7 | |||||||||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.account-payables | -0.85 | 12.4 | -8.1 | -2.6 | |||||||||||||||||
cash-flows.row.other-working-capital | 3.37 | -2 | 2.9 | 12.7 | |||||||||||||||||
cash-flows.row.other-non-cash-items | 1096.45 | 1068.2 | 1.7 | 25.2 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 148.24 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.33 | -0.3 | -0.1 | -0.3 | |||||||||||||||||
cash-flows.row.acquisitions-net | -1026.05 | -1026 | 0 | 0 | |||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.other-investing-activites | -1022.12 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -1026.37 | -1026.3 | -0.1 | -0.3 | |||||||||||||||||
cash-flows.row.debt-repayment | -520.41 | -300 | -120.7 | 0 | |||||||||||||||||
cash-flows.row.common-stock-issued | 2.38 | 6.4 | 9.5 | 19.6 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | -126.4 | -24.1 | |||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | -111.2 | 0 | |||||||||||||||||
cash-flows.row.other-financing-activites | 700.67 | 570.8 | 111.2 | -4.5 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 257.62 | 277.2 | -237.6 | -4.5 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | -34.99 | -0.1 | 0 | 0 | |||||||||||||||||
cash-flows.row.net-change-in-cash | -620.03 | -565.3 | 36.1 | 257.1 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 501.77 | 92.2 | 657.9 | 621.9 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 1121.8 | 657.5 | 621.9 | 364.8 | |||||||||||||||||
cash-flows.row.operating-cash-flow | 148.24 | 183.4 | 273.8 | 261.9 | |||||||||||||||||
cash-flows.row.capital-expenditure | -0.33 | -0.3 | -0.1 | -0.3 | |||||||||||||||||
cash-flows.row.free-cash-flow | 147.91 | 183.2 | 273.6 | 261.6 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 413.55 | 442.7 | 410.6 | 413.8 | |||||||||||||||||
income-statement-row.row.cost-of-revenue | 1.29 | 1.6 | 1.4 | 1.5 | |||||||||||||||||
income-statement-row.row.gross-profit | 412.26 | 441.2 | 409.2 | 412.2 | |||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.research-development | 1218.89 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-expenses | 5.62 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.operating-expenses | 1382.59 | 232.1 | 160.3 | 181.5 | |||||||||||||||||
income-statement-row.row.cost-and-expenses | 1383.54 | 233.7 | 160.3 | 181.5 | |||||||||||||||||
income-statement-row.row.interest-income | 12.87 | 19 | 9.5 | 0.7 | |||||||||||||||||
income-statement-row.row.interest-expense | 12.87 | 21.6 | 7.6 | 31.1 | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -37.81 | -1157.1 | 2.1 | -31.6 | |||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-operating-expenses | 5.62 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.total-operating-expenses | -37.81 | -1157.1 | 2.1 | -31.6 | |||||||||||||||||
income-statement-row.row.interest-expense | 12.87 | 21.6 | 7.6 | 31.1 | |||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 22.79 | 1.6 | 9.5 | 0.7 | |||||||||||||||||
income-statement-row.row.ebitda-caps | -958.97 | - | - | - | |||||||||||||||||
income-statement-row.row.operating-income | -987.69 | 209 | 250.3 | 232.3 | |||||||||||||||||
income-statement-row.row.income-before-tax | -1008.97 | -948.1 | 252.4 | 200.7 | |||||||||||||||||
income-statement-row.row.income-tax-expense | 54.22 | 83.5 | 77.4 | -327.8 | |||||||||||||||||
income-statement-row.row.net-income | -1033.88 | -1002.2 | 175.1 | 528.4 |
Vaak gestelde vragen
Wat is Ironwood Pharmaceuticals, Inc. (IRWD) totale activa?
Ironwood Pharmaceuticals, Inc. (IRWD) totale activa is 471073000.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is 192430000.000.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.996.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is -2.264.
Wat is de totale omzet van de onderneming?
De totale opbrengst is -2.120.
Wat is Ironwood Pharmaceuticals, Inc. (IRWD) nettowinst (netto-inkomen)?
De nettowinst is -1002239000.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 715538000.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 232124000.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 121540000.000.